Table 3.

Tabular representation of the reported outcomes of the meta-analyses.

Outcome	Meta-analysis	Studies	Patients	ES	95% lower CI	95% upper CI	I2, %	P
Early complications	Shenoy et al.33	9	2240	0.71	0.44	1.13	38	0.012
	Chenxin Xu et al.12	19	31 941	1.75	1.51	2.04	0	0.69
Late complication	Shenoy et al.33	9	2240	0.35	0.19	0.65	0	0.46
	Chenxin Xu et al.12	19	31 941	1.63	1.41	1.88	0	0.48
Total complication	Vallois et al.34 for RYGB	11	6638	1.70	0.98	2.94	76	0.001
	Vallois et al.34 for SG	9	26 118	1.49	1.28	1.75	48	0.04
	Giordano et al.32	11	2259	1.71	0.76	3.83	83	<0.001
	Giordano et al.31	7	3128	1.51	1.07	2.11	0	0.99
	Marczuk et al.26	9	4391	1.88	1.07	3.30	50	0.05
Mortality	Shenoy et al.33	9	2240	0.50	0.15	1.70	0	0.45
	Chenxin Xu et al.12	19	31 941	Early: 2.23; late: 1.22	Early: 1.37; late: 0.18	Early: 3.64; late: 8.06	Early: 37; late: 56	Early: 0.19; late: 0.10
	Giordano et al.31	7	3128	6.12	1.08	34.43	44	0.13
	Marczuk et al.26	9	4391	4.38	1.25	15.31	18	0.3
Early readmission	Chenxin Xu et al.12	19	31 941	1.75	1.48	2.06	0	0.53
Reoperation	Chenxin Xu et al.12	19	31 941	2.16	1.67	2.81	12	0.34
%TWL	Chenxin Xu et al.12	19	31 941	2 years: 6.26; 3 years: 4.97	2 years: −1.33; 3 years: 13.85	2 years: 2.34; 3 years: 12.27	2 years: 80; 3 years: 95	2 years: 0.03; 3 years: <0.001
%EWL	Shenoy et al.33	9	2240	7.79	−23.96	8.38	90	<0.001
	Chenxin Xu et al.12	19	31 941	1 year 19.55; 2 years: 16.56	1 year 14.65; 2 years: 0.05	1 year 24.46; 2 years: 33.08	Early: 28; late: 80	Early: 0.24; late: 0.02
	Giordano et al.32	11	2259	−7.63	−13.19	−2.08	84	<0.001
	Giordano et al.31	7	3128	−3.44	−5.20	−1.68	0	0.87
	Marczuk et al.26	9	4391	−5.86	−9.15	−2.56	0	0.77
	Vallois et al.34 for RYGB	11	6638	−5.28	−7.49	−3.07	0	0.71
	Vallois et al.34 for SG	9	26 118	−4.49	−6.98	−2.01	0	0.74
DLP	Giordano et al.31	7	3128	0.61	0.45	0.83	0	0.54
	Vallois et al.34 for SG	9	26 118	1.37	0.85	2.19	46	0.15
T2DM	Shenoy et al.33	9	2240	1.02	0.63	1.66	0	0.66
	Chenxin Xu et al.12	19	31 941	0.89	0.37	2.13	57	0.10
	Marczuk et al.26	9	4391	0.64	0.42	0.97	0	0.54
	Vallois et al.34 for RYGB	11	6638	0.51	0.30	0.87	—	—
	Vallois et al.34 for SG	9	26,118	1.69	0.79	3.61	82	<0.001
HTN	Shenoy et al.33	9	2240	0.57	0.35	0.93	0	0.58
	Chenxin Xu et al.12	19	31 941	1.73	1.02	2.93	0	0.38
	Giordano et al.31	7	3128	0.57	0.42	0.76	42	0.14
	Marczuk et al.26	9	4391	0.33	0.14	0.74	61	0.08
	Vallois et al.34 for RYGB	11	6638	0.42	0.06	2.89	—	—
	Vallois et al.34 for SG	9	26 118	1.13	0.74	1.74	39	0.16
OSA	Shenoy et al.33	9	2240	1.14	0.55	2.34	0	0.70
	Chenxin Xu et al.12	19	31 941	1.31	0.60	2.81	0	0.56
	Giordano et al.32	11	2259	0.81	0.69	0.95	0	0.96
	Vallois et al.34 for RYGB	11	6638	0.97	0.58	1.65	91	<0.001
	Vallois et al.34 for SG	9	26 118	3.36	0.58	19.43	—	—

EWL, excess weight loss; HTN, hypertension; SG, sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; T2DM, type-2 diabetes mellitus.

TWL, total weight loss; DLP, dyslipidemia; OSA, Obstructive sleep apnea.